1003875-12-4Relevant academic research and scientific papers
Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles
McAtee, John J.,Dodson, Jason W.,Dowdell, Sarah E.,Erhard, Karl,Girard, Gerald R.,Goodman, Krista B.,Hilfiker, Mark A.,Jin, Jian,Sehon, Clark A.,Sha, Deyou,Shi, Dongchuan,Wang, Feng,Wang, Gren Z.,Wang, Ning,Wang, Yonghui,Viet, Andrew Q.,Yuan, Catherine C.K.,Zhang, Daohua,Aiyar, Nambi V.,Behm, David J.,Carballo, Luz H.,Evans, Christopher A.,Fries, Harvey E.,Nagilla, Rakesh,Roethke, Theresa J.,Xu, Xiaoping,Douglas, Stephen A.,Neeb, Michael J.
scheme or table, p. 3716 - 3719 (2009/04/04)
Lead compound 1 was successfully redesigned to provide compounds with improved pharmacokinetic profiles for this series of human urotensin-II antagonists. Replacement of the 2-pyrrolidinylmethyl-3-phenyl-piperidine core of 1 with a substituted N-methyl-2-
MORPHOLINYL AND PYRROLIDINYL ANALOGS
-
Page/Page column 104, (2008/06/13)
The present invention relates to morpholinyl, and pyrrolidinyl analogs, pharmaceutical compositions containing them, and their use as antagonists of urotensin II.
